Biochips as Pathways to Drug Discovery

ISBN-13: 9781574444506 / Angielski / Twarda / 2006 / 386 str.

Andrew Carmen; Gary Hardiman

Opis

In the fiercely competitive pharmaceutical marketplace, your organization cannot afford to spend excess dollars developing drugs that will fail to get FDA approval or have profoundly poor characteristics. Biochips as Pathways to Drug Discovery takes a comprehensive look at how the industry faces these challenges, using new technologies such as biochips to reduce the cost of drug discovery and improve drug safety. The book explores the tools and skills required at each step of the discovery process when using biochips to determine biological outcomes. The authors provide an in-depth review of the clinical and pharmacogenomic relevance of biochips, ChIP-chip assays, and high-throughput approaches. They discuss how biochips are used to develop biomarkers in the drug discovery process, primarily for gene expression profiling and Single Nucleotide Polymorphism (SNP) analysis. The book includes coverage of experimental theory, quality control, clinical laboratory sampling considerations, database concepts, industrial laboratory design, and the analysis of the resultant large data sets. It discusses the application of biochips to the study of malaria, toxicogenomics, and SNPs, as well as intellectual property and market overviews. The book concludes with a comprehensive overview of how these chips are employed from early target discovery through preclinical toxicology and on through to pharmacogenomic and proof of concept studies in humans. Written in an easily accessible style, the breadth of coverage introduces the subject to those new to the field, while the depth of coverage forms a foundation for future work. The book gives you the knowledge required to leverage the technology into bona fide discoveries. Daniel E. Levy, editor of the Drug Discovery Series, is the founder of DEL BioPharma, a consulting service for drug discovery programs. He also maintains a blog that explores organic chemistry.

Spis treści

DNA Biochips — Past, Present, and Future: An Overview. Three-Dimensional HydroArrays: Novel Microarrays for Genomic and Proteomic Studies. Biochip in Malaria for Antiparasitic Discovery. Regional Variations in Intestinal ATP-Binding Cassette Transporter Expression Identified with a Global Error Assessment Model. Toxicogenomics in Drug Safety Evaluation: Bridging Drug Discovery and Development. The Next Generation of Automated Microarray Platforms for a Multiplexed CYP2D6 Assay. Biopsy and RNA Extraction Procedures of Muscle and Adipose Tissue for Microarray Gene-Expression Profiling. ChIP-on-Chip: Analysis of Genomewide Protein Binding and Posttranslational Modifications. DNA Microarrays as Functional Genomics Tools for Cancer Drug Discovery. High-Throughput Microarray Analysis. Laboratory Automation: Strategies for High-Volume Industrial Microarray Programs. Association Studies: Practical and Theoretical Considerations for Drug Discovery, Evaluation, and Beyond. Approaches for Microarray Data Validation. Microarray Enterprise Information Management: What Is It and Why Is It Important? Quality Control of Microarray Data. Microarray Data Normalization and Transformation. Amplification Strategies and DNA Biochips. Ribo-SPIA™, a Rapid Isothermal RNA Amplification Method for Gene Expression Analysis. Genomics, Transcriptomics, and Proteomics: Novel Detection Technologies and Drug Discovery. Intellectual Property Issues for DNA Chips and Microarrays. Biochips: Market Drivers and Commercial Prospect. A Pharmaceutical Perspective for Microarrays and Biochips: Current-Market Overview and Future Trends.

O autorze

Gary Hardiman